Dr. Hasniza  Binti Zaman Huri
My Social Links

Dr. Hasniza Binti Zaman Huri

Associate Professor
University of Malaya, Malaysia


Highest Degree
Ph.D. in Clinical Pharmacy from Universiti Kebangsaan Malaysia, Malaysia

Share this Profile

Area of Interest:

Pharmacology and Toxicology
100%
Clinical Pharmacy
62%
Gynaecology
90%
Diabetes Mellitus
75%
Gene Expression
55%

Research Publications in Numbers

Books
0
Chapters
0
Articles
0
Abstracts
0

Selected Publications

  1. Zaini, S., N.C. Guan, A.H. Sulaiman, N.Z. Zainal, H.Z. Huri and S.H. Shamsudin, 2018. The use of antidepressants for physical and psychological symptoms in cancer. Curr. Drug Targets, 19: 1431-1455.
    CrossRef  |  Direct Link  |  
  2. Zaini, S., H.A.M. Bharathy, A.H. Sulaiman, J.S. Gill and K.O. Hui et al., 2018. Development of a strategic tool for shared decision-making in the use of antidepressants among patients with major depressive disorder: A focus group study. Int. J. Environ. Res. Public Health, Vol. 15. 10.3390/ijerph15071402.
    CrossRef  |  PubMed  |  
  3. Ying, T.J., Z.A. Zainal, I.A. Wahab, F. Zamri and H.Z. Huri, 2018. Attitude and self-medication practice on antibiotic use amongst general public in Alor Setar, Kedah, Malaysia. Madridge J. Pharm. Res., 2: 40-46.
  4. Razali, N.R., H.Z. Huri, L. Ibrahim, S.R. Vethakkan and B.M. Abdullah, 2018. Glycemic effects of simvastatin: Where do we stand? Braz. J. Pharm. Sci., Vol. 54. 10.1590/s2175-97902018000117192.
    CrossRef  |  Direct Link  |  
  5. Mark, R., H.Z. Huri and A.H.A. Razack, 2018. Demographic, clinical and lifestyle predictors for severity of erectile dysfunction and biomarkers level in Malaysian patients. Braz. J. Pharm. Sci., Vol. 54. 10.1590/s2175-97902018000317552.
    CrossRef  |  Direct Link  |  
  6. Huri, H.Z., C.C. Huey, N. Mustafa, N.F. Mohamad and T.A. Kamalden, 2018. Association of glycemic control with progression of diabetic retinopathy in type 2 diabetes mellitus patients in Malaysia. Braz. J. Pharm. Sci., Vol. 54. 10.1590/s2175-97902018000217484 .
    CrossRef  |  Direct Link  |  
  7. Elnaem, M.H., M.H.N. Mohamed, H.Z. Huri and S.M. Azarisman, 2018. Impact of educational outreach intervention on enhancing health care providers' knowledge about statin therapy prescribing in Malaysian patients with type 2 diabetes mellitus. J. Eval. Clin. Pract., 24: 521-527.
    CrossRef  |  Direct Link  |  
  8. Abu Bakar, M.H., H.Z. Huri and N. Hairunisa, 2018. Reduced mitochondrial DNA content in lymphocytes is associated with insulin resistance and inflammation in patients with impaired fasting glucose. Clin. Exp. Med., 18: 373-382.
  9. Zaini, S., C.G. Ng, A.H. Sulaiman, N.Z. Huri and S.H. Shamsudin, 2017. A review of the use of mirtazapine in cancer patients. Malaysian J. Psychiatry, Vol. 25. .
    Direct Link  |  
  10. Perumalsamy, S., N.A.A.M. Zin, R.T. Widodo, W.A.W. Ahmad, S.R.D.B. Vethakkan and H.Z. Huri, 2017. Chemokine Like Receptor-1 (CMKLR-1) receptor: A potential therapeutic target in management of chemerin induced type 2 diabetes mellitus and cancer. Curr. Pharmaceut. Des., 23: 3689-3698.
    CrossRef  |  PubMed  |  Direct Link  |  
  11. Huri, H.Z., L.C. Fang and A.H. Abdul Razack, 2017. Drug-related problems in patients with erectile dysfunctions and multiple co-morbidities. Ther. Clin. Risk Manage., 13: 407-419.
  12. Huri, H.Z., C.K. Hui and L. Ibrahim, 2017. Utilisation of Variable Rate Intravenous Insulin Infusion. LAP LAMBERT Academic Publishing, Germany.
  13. Elnaem, M.H., M.H.N. Mohamed, H.Z. Huri, M. Shah and A. Shah, 2017. Patterns of statin therapy prescribing among hospitalized patients with type 2 diabetes mellitus in two Malaysian tertiary hospitals. Trop. J. Pharm. Res., 16: 3005-3011.
    Direct Link  |  
  14. Elnaem, M.H., M.H. Mohamed, H.Z. Huri, S.M. Azarisman and R.M. Elkalmi, 2017. Statin therapy prescribing for patients with type 2 diabetes mellitus: A review of current evidence and challenges. J. Pharm. Bioall. Sci., 9: 80-87.
  15. Babaei, M.A., H.Z. Huri, B. Kamalidehghan, S.K. Yeap and F. Ahmadipour, 2017. Apoptotic induction and inhibition of NF- B signaling pathway in human prostatic cancer PC3 cells by natural compound 2,2 -oxybis (4-allyl-1-methoxybenzene), biseugenol B, from Litsea costalis: An in vitro study. OncoTargets Therapy, 10: 277-294.
  16. Ahmed, R.H., H.Z. Huri, S. Muniandy, Z. Al-Hamodi, B. Al-Absi, A. Alsalahi and M.F. Razif, 2017. Altered circulating concentrations of active glucagon-like peptide (GLP-1) and dipeptidyl peptidase 4 (DPP4) in obese subjects and their association with insulin resistance. Clin. Biochem., 50: 746-749.
    CrossRef  |  Direct Link  |  
  17. Abu Bakar, M.H., M.R. Sarmidi, H.Z. Huri and N. Hairunisa, 2017. Alterations of cultured myotubes and fasting plasma metabolite profiles related to mitochondrial dysfunction in Type 2 diabetes subjects. Free Radic. Biol. Med., 112: 165-165.
    CrossRef  |  Direct Link  |  
  18. Loganadan, N.K., H.Z. Huri, S.R. Vethakkan and Z. Hussein, 2016. Genetic markers predicting sulphonylurea treatment outcomes in type 2 diabetes patients: Current evidence and challenges for clinical implementation. Pharmacogenomics J., 16: 209-219.
    CrossRef  |  Direct Link  |  
  19. Loganadan, N.K., H.Z. Huri, S.R. Vethakkan and Z. Hussein, 2016. Association of rs5219 KCNJ11 gene polymorphism with pancreatic beta-cell function, insulin resistance and glycemic control of sulfonylurea-treated Malaysian type 2 diabetes patients. Diabetes, 65: A428-A428.
  20. Kasim, N.B., H.Z. Huri, S.R. Vethakkan, L. Ibrahim and B.M. Abdullah, 2016. Genetic polymorphisms associated with overweight and obesity in uncontrolled Type 2 diabetes mellitus. Biomarkers Med., 10: 403-415.
  21. Jamaluddin, J.L., H.Z. Huri and S.R. Vethakkan, 2016. Clinical and genetic predictors of dipeptidyl peptidase-4 inhibitor treatment response in type 2 diabetes mellitus. Pharmacogenomics, 17: 867-881.
  22. Huri, H.Z., N.D.M. Sanusi, A.H.A. Razack and R. Mark, 2016. Association of psychological factors, patients’ knowledge and management among patients with erectile dysfunction. Patient Preference Adherence, 10: 807-823.
    CrossRef  |  Direct Link  |  
  23. Huri, H.Z., M.I. Abdul Aziz, S.R. Vethakkan and R.T. Widodo, 2016. Factors associated with hypoglycemia episodes in hospitalized type 2 diabetes mellitus patients in a tertiary health facility in Malaysia. Trop. J. Pharmaceut. Res., 15: 1313-1320.
    CrossRef  |  Direct Link  |  
  24. Balakrishnan, K.V., B.M. Abdullah, R. Alsayed, H.Z. Huri, N. Hairunisa, A.E. Ibrahim and E. Yousif, 2016. A study on cloning and expression of HIV-1 NEF protein in HEK 293 cells by transient transfection. Res. J. Pharm. Biol. Chem. Sci., 7: 1318-1330.
    Direct Link  |  
  25. Baig, S., I. Seevasant, J. Mohamad, A. Mukheem, H.Z. Huri and T. Kamarul, 2016. Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand? Cell Death Dis., Vol. 7. 10.1038/cddis.2015.275.
    CrossRef  |  Direct Link  |  
  26. Babaei, M.A., B. Kamalidehghan, M. Saleem, H.Z. Huri and F. Ahmadipour, 2016. Receptor tyrosine kinase (c-Kit) inhibitors: A potential therapeutic target in cancer cells. Drug Des. Dev. Therapy, 10: 2443-2459.
    CrossRef  |  PubMed  |  Direct Link  |  
  27. Ahmed, R.H., H.Z. Huri, Z. Al-Hamodi, S.D. Salem, B. Al-Absi and S. Muniandy, 2016. Association of DPP4 gene polymorphisms with type 2 diabetes mellitus in Malaysian subjects. PLoS One, Vol. 11. 10.1371/journal.pone.0154369.
    CrossRef  |  Direct Link  |  
  28. Abdullah, B.M., S.I. Zubairi, H.Z. Huri, N. Hairunisa, E. Yousif and R.C. Basu, 2016. Polyesters based on linoleic acid for biolubricant basestocks: Low-temperature, tribological and rheological properties. PLoS One, Vol. 11. 10.1371/journal.pone.0151603.
    CrossRef  |  Direct Link  |  
  29. Loganadana, N.K., H.Z. Huria, S.R. Vethakkanc and Z. Husseind, 2015. Impact of single nucleotide polymorphisms (SNPs) of type 2 diabetes (T2D) genes on patients’ response to sulphonylurea therapy. Public Health Genomics, 18: 1-51.
  30. Jamaluddin, J.L., H.Z. Huri, S.R. Vethakkan, N. Mustafa and W.A.W. Ahmad, 2015. Pathway mechanism of potential genomic markers of dipeptidyl peptidase-4 inhibitor treatment response in type 2 diabetes. Public Health Genomics, 18: 9-9.
  31. Huri, H.Z., L.P. Lim and S.K. Lim, 2015. Glycemic control and antidiabetic drugs in type 2 diabetes mellitus patients with renal complications. Drug Des. Dev. Therapy, 9: 4355-4371.
    CrossRef  |  Direct Link  |  
  32. Huri, H.Z., D.L.Y. Hui and W.A.W. Ahmad, 2015. Association between glycemic control and antidiabetic drugs in type 2 diabetes mellitus patients with cardiovascular complications. Drug Des. Dev. Therapy, 2015: 4735-4749.
    CrossRef  |  Direct Link  |  
  33. Huri, H.Z., B.M. Abdullah and E. Yousif, 2015. Biolubricant Base Oil Synthesis and Its Applications: Pharmaceutical and Industrial Applications Based on Environmentally Friendly. LAP Lambert Academic Publishing, Germany, ISBN-13: 9783659713316, Pages: 84.
  34. Hassan, F., A. Abdul Hameed, A. Alshanon, B.M. Abdullah, H.Z. Huri, N. Hairunisa and E. Yousif, 2015. Antitumor activity for gold (III) complex by high content screening technique (HCS) and cell viability assay. Asian J. Biochem., 10: 252-266.
    CrossRef  |  
  35. Balakrishnan, K.V., B.M. Abdullah, H.Z. Huri, N. Hairunisa and N.M. Yusoff, 2015. A review on biologically active N-myristoylated HIV-1 Nef protein. Asian J. Biochem., 10: 242-251.
    CrossRef  |  
  36. Almualm, Y. and H.Z. Huri, 2015. Chronic kidney disease screening methods and its implication for Malaysia: An in depth review. Global J. Health Sci., 7: 96-109.
  37. Ahmed, R.H., Z. Al-Hamodi, S.D. Salem, H.Z. Huri and S. Muniandy, 2015. Association of genetic polymorphisms of dipeptidyl peptidase-4 with metabolic syndrome parameters in malaysian subjects. Public Health Genomics, 18: 1-51.
  38. Ahmed, R.H., H.Z. Huri, Z. Al-Hamodi, S.D. Salem and S. Muniandy, 2015. Serum levels of soluble CD26/dipeptidyl peptidase-IV in type 2 diabetes mellitus and its association with metabolic syndrome and therapy with antidiabetic agents in Malaysian subjects. PLoS One, Vol. 10. 10.1371/journal.pone.0140618.
    CrossRef  |  Direct Link  |  
  39. Abu Bakar, M.H., M.R. Sarmidi, K.K. Cheng, A.A. Khan, L.S. Chua, H.Z. Huri and H. Yaakob, 2015. Metabolomics-the complementary field in systems biology: A review on obesity and type 2 diabetes. Mol. Biosyst., 11: 1742-1774.
    CrossRef  |  Direct Link  |  
  40. Abu Bakar, M.H., M.R. Sarmidi, H. Yaakob, C.K. Kai and H.Z. Huri, 2015. JNK signaling pathways is required for mitochondrial dysfunction-induced iinsulin resistance in wrl-68 human liver cell. Diabetes Technol. Ther., 17: A154-A155.
  41. Abu Bakar, M.H., K.K. Cheng, M.R. Sarmidi, H. Yaakob and H.Z. Huri, 2015. Celastrol protects against antimycin A-induced insulin resistance in human skeletal muscle cells. Molecules, 20: 8242-8269.
    CrossRef  |  Direct Link  |  
  42. Abu Bakar, M.H., C.K. Kai, W.N.W. Hassan, M.R. Sarmidi, H. Yaakob and H.Z. Huri, 2015. Mitochondrial dysfunction as a central event for mechanisms underlying insulin resistance: The roles of long chain fatty acids. Diabetes/Metab. Res. Rev., 31: 453-475.
    CrossRef  |  Direct Link  |  
  43. Abdullah, B.M., H.Z. Huri and N. Hairunisa, 2015. Hydrolysis, Separation and Purification of Fatty Acids for Bioproducts. LAP Lambert Academic Publishing, Germany, ISBN-13: 978-3659745010, Pages: 80.
  44. Sarker, M.M.R., K.N. Islam, H.Z. Huri, M. Rahman and H. Imam et al., 2014. Studies of the impact of occupational exposure of pharmaceutical workers on the development of antimicrobial drug resistance. J. Occup. Health, 56: 260-270.
    CrossRef  |  PubMed  |  Direct Link  |  
  45. Jamaluddin, J.L., H.Z. Huri, S.R. Vethakkan and N. Mustafa, 2014. Pancreatic gene variants potentially associated with dipeptidyl peptidase-4 inhibitor treatment response in type 2 diabetes. Pharmacogenomics, 15: 235-249.
  46. Ikmal, H.S.S., Z.H. Huri, V. Vethakkan and W.W. Ahmad, 2014. Potential biomarkers for insulin resistance and atherosclerosis among type 2 diabetes mellitus patients with coronary artery disease. Obes. Rev., Vol. 15. .
    Direct Link  |  
  47. Huri, H.Z., V. Permalu and S.R. Vethakkan, 2014. Sliding-scale versus basal-bolus insulin in the management of severe or acute hyperglycemia in type 2 diabetes patients: A retrospective study. PLoS One, Vol. 9. 10.1371/journal.pone.0106505.
    CrossRef  |  Direct Link  |  
  48. Huri, H.Z., T.L. Choo, C.Z. Sulaiman, R. Mark and A.H. Abdul Razack, 2014. Oral drug treatments in subjects with erectile dysfunction and multiple comorbidities: A retrospective observational study. BMJ Open, Vol. 4. 10.1136/bmjopen-2014-005381.
    CrossRef  |  
  49. Huri, H.Z., N. Selamat and S.R. Vethakkan, 2014. Factors associated with utilization of dipeptidyl-4 inhibitors in patients with type 2 diabetes mellitus: A cross-sectional retrospective study. Int. J. Endocrinol., Vol. 2014. 10.1155/2014/367564.
    CrossRef  |  Direct Link  |  
  50. Huri, H.Z., M. Makmor-Bakry, R. Hashim, N. Mustafa and W.Z.W. Ngah, 2014. Effect of interaction between polymorphisms in the insulin receptor substrate genes in type 2 diabetes mellitus patients with severe/acute hyperglycemia. Trop. J. Pharm. Res., 13: 889-894.
  51. Huri, H.Z., M. Makmor-Bakry, R. Hashim, N. Mustafa and W.Z.W. Ngah, 2014. A prospective cohort study of IRS genes polymorphisms in type 2 diabetes mellitus patients during severe/acute hyperglycemia phase: Part 1: Association with insulin resistance. Trop. J. Pharm. Res., 13: 895-901.
  52. Huri, H.Z., M. Makmor-Bakry, R. Hashim, N. Mustafa and W.Z.W. Ngah, 2014. A prospective cohort study of IRS genes polymorphisms in type 2 diabetes mellitus patients during severe/acute hyperglycemia phase. 2: Association with glycemic control. Trop. J. Pharm. Res., 13: 903-906.
    CrossRef  |  Direct Link  |  
  53. Huri, H.Z., C.H. Xin and C.Z. Sulaiman, 2014. Drug-related problems in patients with benign prostatic hyperplasia: A cross sectional retrospective study. PLoS One, Vol. 9. 10.1371/journal.pone.0086215.
    CrossRef  |  Direct Link  |  
  54. Huri, H.Z. and L.T. Xiang, 2014. Factors associated with treatment response to antidiabetic agents in compliant type 2 diabetes mellitus patients: A brief summary of 5-year data. Trop. J. Pharm. Res., 13: 429-435.
    CrossRef  |  Direct Link  |  
  55. Derawi, D., B.M. Abdullah, H.Z. Huri, R.M. Yusop, J. Salimon, N. Hairunisa and N. Salih, 2014. Palm olein as renewable raw materials for industrial and pharmaceutical products applications: Chemical characterization and physicochemical properties studies. Adv. Mater. Sci. Eng., Vol. 2014. 10.1155/2014/134063.
    CrossRef  |  Direct Link  |  
  56. Abu Bakar, M.H., M.R. Sarmidi, C.K. Kai, H.Z. Huri and H. Yaakob, 2014. Amelioration of mitochondrial dysfunction-induced insulin resistance in differentiated 3T3-L1 adipocytes via inhibition of NF-κB pathways. Int. J. Mol. Sci., 15: 22227-22257.
    CrossRef  |  Direct Link  |  
  57. Ikmal, S., S.I. Qhadijah, H.Z. Huri, S.R. Vethakkan, W. Ahmad and W. Azman, 2013. Potential biomarkers of insulin resistance and atherosclerosis in type 2 diabetes mellitus patients with coronary artery disease. Int. J. Endocrinol., Vol. 2013. 10.1155/2013/698567.
    CrossRef  |  Direct Link  |  
  58. Huri, H.Z., V. Permalu and N.B. Kasim, 2013. Management of severe/acute hyperglycemia in hospitalised type 2 diabetes mellitus patients. J. Endocrinol. Diabetes Mellitus, 1: 9-14.
  59. Huri, H.Z., M. Makmor-Bakry, R. Hashim, N. Mustafa and W.Z.W. Ngah, 2013. Demographic and clinical predictors for insulin resistance in type 2 diabetes mellitus patients during severe/acute hyperglycemia phase. Lat. Am. J. Pharm., 32: 120-127.
  60. Huri, H.Z. and L.C. Ling, 2013. Drug-related problems in type 2 diabetes mellitus patients with dyslipidemia. BMC Public Health, Vol. 13. 10.1186/1471-2458-13-1192.
    CrossRef  |  
  61. Huri, H.Z. and H.F. Wee, 2013. Drug related problems in type 2 diabetes patients with hypertension: A cross-sectional retrospective study. BMC Endocrine Disord., Vol. 13. 10.1186/1472-6823-13-2.
    CrossRef  |  Direct Link  |  
  62. Thomas, P.T., A.A. Shafie, C.S. Siang, M.A.A. Hassali and M.H.N. Mohamed et al., 2012. Training Manual for Pharmacists for Management of Obesity and Overweight. Malaysia Academy of Pharmacy/Malaysian Pharmaceutical Society, Malaysia.
  63. Huri, H.Z., M. Makmor-Bakry, R. Hashim, N. Mustafa and W.Z.W. Ngah, 2012. Optimisation of glycaemic control during episodes of severe/acute hyperglycaemia in patients with type 2 diabetes mellitus. Int. J. Clin. Pharm., 34: 863-870.
    CrossRef  |  Direct Link  |  
  64. Huri, H.Z., 2012. Dyslipidemia and Type 2 Diabetes Mellitus: Implications and Role of Antiplatelet Agents in Primary Prevention of Cardiovascular Disease. In: Dyslipidemia-From Prevention to Treatment, Kelishadi, R. (Ed.). InTech Publisher, Rijeka, Croatia, ISBN: 978-953-307-904-2, pp: 79-92.
  65. Huri, H.Z., A.T.L. Wei, R. Pendek, C.Z. Sulaiman and R.T. Widodo, 2010. Factors influencing utilization of different types of sulphonylureas amongst type 2 diabetes patients. Lat. Am. J. Pharm., 29: 1044-1048.
    Direct Link  |  
  66. Huri, H.Z., G.T.P. Lian, S. Hussain, R. Pendek and R.T. Widodo, 2009. A survey amongst Complementary Alternative Medicine (CAM) users with type 2 diabetes. Int. J. Diabetes Metab., 17: 9-15.
  67. Huri, H.Z., G.T.K. Foong, R. Pendek and R.T. Widodo, 2009. Different characteristics of diabetic ketoacidosis between type 1 and type 2 diabetes patients in Malaysia. Asian Biomed., 3: 201-205.
    Direct Link  |  
  68. Huri, H.Z., O.C. Wen and R. Pendek, 2008. Self-monitoring blood glucose (SMBG) in type 2 diabetics in Malaysia. Asian Biomed., 2: 335-340.
  69. Huri, H.Z., L.Q. Yi, R. Pendek and C.Z. Sulaiman, 2008. Utilization of antiplatelet agents for primary and secondary prevention of cardiovascular disease amongst type 2 diabetics. J. Pharm. Pract., 21: 287-301.
  70. Huri, H.Z., Y.S. Min and R. Pendek, 2007. Episodes of hypoglycemia and hyperglycemia during the use of sliding scale insulin in hospitalized diabetes patients. Asian Biomed., 1: 307-311.